Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower
left ventricular outflow tract (LVOT) gradients and improve heart failure symptoms in patients …

The study of cardiac physiology is hindered by physiological differences between humans
and small-animal models. Here we report the generation of multi-chambered self-paced …

Muscle weakness is a hallmark of inherited or acquired myopathies. It is a major cause of
functional impairment and can advance to life-threatening respiratory insufficiency. During …

Background Women with heart failure with reduced ejection fraction (HFrEF) receive less
guideline-recommended therapy and experience worse quality of life than men. Objectives …

Aim N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is predictive of both outcomes
and response to treatment in patients with heart failure with reduced ejection fraction …

Titin-truncating variants (TTNtv) are the single largest genetic cause of dilated
cardiomyopathy (DCM). In this study we modeled disease phenotypes of A-band TTNtv …

Despite recent advances in chronic heart failure (HF) management, the prognosis of HF
patients is poor. This highlights the need for researching new drugs targeting, beyond …

Aims Heart failure with reduced ejection fraction (HFrEF) is a disease with high mortality and
morbidity. Recent positive inotropic drug developments focused on cardiac myofilaments …

Heart failure (HF) is a rapidly growing pandemic while medical treatment options remain
limited. Omecamtiv mecarbil (OM) is a novel HF drug that directly targets the myosin heads …

Abstract Purpose of Review Cardiac myosin inhibitors (CMIs) and activators are emerging
therapies for hypertrophic cardiomyopathy (HCM) and heart failure with reduced ejection …